Pretilachlor Rout Slashes FY27 Growth Guidance; Long-Term Capex Intact
Q1 revenue fell 8.5% as erratic monsoon crippled herbicide demand, and management cut full-year growth guidance from ≥20% to lower single-digit. One-time charges obscure the fact that normalized margins remained resilient, and capex plans for the ₹1,000 crore Hamirpur facility by FY30 are on track.
₹251.8 Cr
-8.5% YoY vs ≥20% FY27 guidance
₹22.8 Cr
-34.8% YoY
₹8.5 Cr
₹2.5 Cr write-off + ₹6 Cr job work
~18.5%
ex one-offs; reported 15.4%
How the Quarter Unfolded
India Pesticides guided ≥20% full-year FY27 growth on its prior call. Q1 delivered -8.5% revenue YoY, and management downgraded full-year guidance to 'lower single-digit growth'—a dramatic reversal. Net profit crashed -34.8% YoY, but the company disclosed ₹8.5 crore in one-time charges (a ₹2.5 crore export receivable write-off and ₹6 crore in job work for herbicide intermediates that didn't sell). Strip those out, and normalized EBITDA margin runs ~18.5%—not great, but defensible given the monsoon disruption.
The Demand Collapse That Triggered the Cut
The culprit was clear: Pretilachlor, the herbicide for paddy crops, fell 13% in volume as erratic monsoon rains delayed sowing across the country. Domestic revenue contracted to ₹167 crore from ₹195 crore a year ago. Management offered a 4% price increase to cushion the blow, but pricing power is limited when demand itself is collapsing. The company pivoted to long-term strategy on the call—committing to three new molecules (fungicide, herbicide import-replacement, herbicide multipurpose) and reaffirming capex plans for the Hamirpur facility (₹1,000 crore target by FY30, with 8–10 production blocks in the master plan but only 2 live today). The message: near-term pain, long-term ambition.
We have expected a good volume of herbicide. So we have converted a lot of raw material into intermediate, which will be consumed in next 2 to 3 months.
Softer domestic demand hit Pretilachlor volumes.
Volume -13%, price +4%. Domestic revenue ₹167 Cr vs ₹195 Cr YoY. Monsoon-driven.
Supported
₹8.5 Cr one-time charges impaired Q1 EBITDA.
₹2.5 Cr export receivable write-off + ₹6 Cr job work for unsold herbicide intermediates.
Supported
FY27 will achieve lower single-digit growth.
Q1 at -8.5% YoY; prior call guided ≥20% FY27. Guidance cut from 20% to <10%.
Contradicted
Hamirpur will deliver ₹50–60 Cr in FY27.
Prior implied ₹70–100 Cr. Only 2/10 blocks live; 1 more this year. Revised down.
Overstated (prior expectation)
EU TEQ approval opens ₹30–40 Cr incremental revenue from Nov 2026.
Approval is real; prior base ₹100 Cr. Sales depend on customer approvals (1–2 months estimated).
Unverified (credible, forward-looking)
What Changed on This Call
FY27 growth guidance: cut from ≥20% to lower single-digit
Hamirpur FY27 target: revised ₹50–60 Cr (down from ₹70–100 Cr implied)
EBITDA margin target: moderated to 15–18% (from 18–20% prior)
Product diversification: 3 new molecules in FY27 to reduce Pretilachlor concentration
EU TEQ approval: fungicide direct-market access, ₹30–40 Cr incremental revenue from Nov
How the Street Is Positioned
The market reacted sharply. The result was announced on Sat Aug 01 2026 at ₹154.15; the stock fell 3.62% on day 1, 5.35% by day 3, and 5.75% by day 5—a sell-off that held without reversal, signaling no bargain-hunting bounce. The stock now trades at ₹138.19 (as of 2026-08-18), down 29.83% from its all-time high of ₹196.93, below all major moving averages (SMA20 ₹146.63, SMA50 ₹154.53, SMA200 ₹160.86). RSI at 13.3 signals deep oversold conditions—but that hasn't arrested the selling pressure. Foreign institutional investors have fled dramatically: FII ownership collapsed from 2.78% (Q2 FY26) to 0.20% (Q1 FY27), a loss of 2.58 percentage points. This is the steepest FII exit in the company's recent history and signals a loss of institutional confidence in near-term recovery. Bulk block activity in the preceding months (May 2026) centered on NK Securities, likely algo rebalancing, with no promoter or insider activity flagged. The narrative: monsoon-hit demand is a known cyclical risk, but the guidance cut from ≥20% to single-digit growth suggests management confidence has eroded faster than the market foresaw.
The Bull-Bear Ledger
Capex roadmap (₹1,000 Cr Hamirpur by FY30) funded from ₹59 Cr cash, no debt
EU TEQ approval real; ₹30–40 Cr incremental revenue from Nov 2026
3 new molecules in FY27 reduce Pretilachlor concentration risk
Normalized EBITDA margin ~18.5% shows core business resilient if demand recovers
Capacity utilization 70%; ample headroom for growth
Q1 revenue down 8.5% vs ≥20% FY27 guidance; guidance cut signals eroded confidence
PAT crashed 34.8% YoY; normalized PAT still depressed
Hamirpur FY27 target revised down ₹20–40 Cr; only 2/10 blocks live
Monsoon volatility ongoing; Pretilachlor concentration persists until new products scale
FII exodus signals institutional confidence wavering; stock down 29.83% from ATH
Ranked Risks
Monsoon-driven demand cyclicality
HighErratic rainfall delayed sowing; Pretilachlor volume -13%. Bad monsoon in FY27 extends softness 2–3 quarters. Core demand risk, not inventory or pricing.
Hamirpur execution and capex ramp
HighOnly 2/10 blocks live; FY27 target revised ₹50–60 Cr (from ₹70–100 Cr implied). ₹1,000 Cr by FY30 requires flawless 3–4 year execution. Any delay cascades.
Product concentration on Pretilachlor
MediumPretilachlor is the dominant product. New molecules (fungicide, herbicide MMP) not yet scaled. Diversification is a 3–4 year journey; dependence persists.
Chinese competition and pricing pressure
MediumChinese agrochemical imports undercut on price. New fungicide import-replacement targets ₹500–600/kg; Chinese likely lower. Capex efficiency and volumes must offset.
Inventory normalization drag
LowBuilt ₹6 Cr job work charges for intermediates; inventory days 200 vs 170 normal. Expected to normalize Q3 as season begins; manageable working-capital headwind.
What to Watch Next
1 · Q2–Q3 monsoon recovery and sowing volume
If rainfall normalizes Sep onward, Pretilachlor demand should recover sharply. Track Q2 volume trends and management commentary on sowing intentions. A solid Q2 volume rebound would validate the 'cyclical trough' narrative; continued softness extends the pain.
2 · Hamirpur FY27 delivery and block ramp progress
Management guided ₹50–60 Cr FY27 revenue from Hamirpur. Track new block commissioning timelines (2nd block fungicide expected Q3–Q4 FY27) and actual revenue contribution. Any delay signals execution risk and pressures the ₹1,000 Cr by FY30 target.
3 · EU TEQ approval fungicide sales traction (from Nov 2026)
EU approval is real, but monetization depends on customer approvals (1–2 months estimated). Watch for order book visibility, customer confirmations, and ramp trajectory toward the ₹30–40 Cr incremental revenue target. This is the nearest concrete upside catalyst.
India Pesticides delivered a messy Q1: volume collapsed 13%, one-time charges inflated the damage, and management slashed full-year guidance from ≥20% growth to 'lower single-digit.' But the underlying story is more nuanced. Normalized EBITDA margin (~18.5%) held up, and the ₹1,000 crore Hamirpur capex roadmap by FY30 remains funded and on track. The real tension is between near-term consolidation (monsoon headwinds, Hamirpur ramp delays) and long-term scale ambition (3 new molecules, EU approval, ₹1,000 Cr facility).
The market's verdict has been swift and harsh: FII ownership collapsed from 2.78% to 0.20%, the stock fell -29.83% from its all-time high and has not bounced, and RSI is deeply oversold. This is less a 'buy the dip' moment and more a signal of institutional loss of confidence in near-term recovery. The guidance cut matters; it telegraphs that management itself is uncertain about the monsoon recovery trajectory.
Hold, not buy. The path to recovery depends on two things: monsoon normalization in Q2–Q3 (which would restore Pretilachlor demand) and Hamirpur execution staying on track (which would deliver the ₹50–60 Cr FY27 target and prove the ₹1,000 Cr vision is credible). Watch Q2 results for volume recovery signals and Hamirpur block commissioning progress. Until those are visible, the -30% drawdown and institutional exit are rational risk-off trades, not panic. The number to track from here is normalized EBITDA progression; if that stays at ~18–19% (before one-offs), the core business holds. If it drops further, the long-term thesis cracks.
Informational and educational content only. Not investment advice.